Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
- 1424.128
- +11.687+0.83%
Over 60% of Companies Post EPS Beats This Week-Earnings Scorecard
Wall Street Today: Market Ends Wild Political TV Day in the Green
Citigroup Maintains Neutral on Intellia Therapeutics, Raises Price Target to $14
Apellis Pharmaceuticals GAAP EPS of -$0.29 Beats by $0.10, Revenue of $212.5M Beats by $14.59M
NewGenIvf Regains Compliance With Nasdaq
JP Morgan Downgrades Intellia Therapeutics to Neutral, Lowers Price Target to $13
Intellia Therapeutics Analyst Ratings
Earnings Scheduled For February 28, 2025
Wall Street Today: Market Decides Down is the Direction
Earnings Call Summary | Intellia Therapeutics(NTLA.US) Q4 2024 Earnings Conference
Apellis Pharmaceuticals Q4 2024 Earnings Preview
Live Stock News: Nvidia Does not run Things Around here Anymore
Amazon Unveils New Quantum Computing Chip, Joining Microsoft and Google
A Glimpse Into The Expert Outlook On Agilent Technologies Through 6 Analysts
Agilent Technologies Analyst Ratings
Earnings Scheduled For February 27, 2025
Earnings Call Summary | Agilent Technologies(A.US) Q1 2025 Earnings Conference
Here's the Major Earnings Before the Open Tomorrow
Wall Street Today: Market Quaking With Anticipation, and Nvidia Delivers Beat
Agilent Technologies Non-GAAP EPS of $1.31 Beats by $0.04, Revenue of $1.68B Beats by $10M